Psyence Biomedical (PBM) has released an update.
Psyence Biomedical has successfully closed its acquisition of Psyence Group’s stake in PsyLabs, enhancing its vertical integration in developing psychedelic therapeutics. This strategic move positions Psyence Biomed to leverage PsyLabs’ expertise in producing pharmaceutical-grade psychedelics, potentially advancing treatments for mental health disorders. The acquisition was facilitated through a debt-for-equity swap, aligning both companies’ interests in the burgeoning psychedelic medicine market.
For further insights into PBM stock, check out TipRanks’ Stock Analysis page.
